Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Post by allain250on Jul 11, 2018 3:02pm
92 Views
Post# 28301699

ICO is about to KIDNAP a HUGE established market

ICO is about to KIDNAP a HUGE established market

ICO is about to KIDNAP a HUGE established market with this new research!
 

DoubleBank Believes the following Scheduled Clinical Trial Reports due this July will prove Explosive concerning the Stock Price of ICO We cannot predict how high ICO stock will travel long term. Although this is a forward looking statement we have every reason to believe stock holders will see nothing but positive results concerning medical trials that have just concluded in Australia on behalf of Ico Therapeutics. The next 2 soon to be seen milestones are a follows: 

 

1.   ORAL B  material pharmacokinetic data to be released in July

2. Bullous Pemphigoid Disease BP-01 material pharmacokinetic data to be released in July

<< Previous
Bullboard Posts
Next >>